Open AccessEarly Changes in Kidney Transplant Immunosuppression Regimens During the COVID-19 Pandemic
Author(s) -
Sunjae Bae,
Mara McAdamsDeMarco,
Allan B. Massie,
JiYoon B. Ahn,
William A Werbel,
Daniel C. Brennan,
Krista L. Lentine,
Christine M. Durand,
Dorry L. Segev
Publication year - 2020
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000003502
Subject(s) - immunosuppression , medicine , basiliximab , pandemic , regimen , kidney transplantation , immunology , transplantation , covid-19 , infectious disease (medical specialty) , disease
Kidney transplant recipients have higher risk of infectious diseases due to their reliance on immunosuppression. During the current COVID-19 pandemic, some clinicians might have opted for less potent immunosuppressive agents to counterbalance the novel infectious risk. We conducted a nationwide study to characterize immunosuppression use and subsequent clinical outcomes during the first 5 months of COVID-19 pandemic in the United States.